These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32901368)

  • 1. Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid.
    Luciani-Giacobbe LC; Lorenzutti AM; Litterio NJ; Ramírez-Rigo MV; Olivera ME
    Drug Deliv Transl Res; 2021 Jun; 11(3):894-908. PubMed ID: 32901368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifampicin-loaded 'flower-like' polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid.
    Moretton MA; Hocht C; Taira C; Sosnik A
    Nanomedicine (Lond); 2014 Aug; 9(11):1635-50. PubMed ID: 24410279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ascorbic acid improves stability and pharmacokinetics of rifampicin in the presence of isoniazid.
    Rajaram S; Vemuri VD; Natham R
    J Pharm Biomed Anal; 2014 Nov; 100():103-108. PubMed ID: 25151231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encapsulating Rifampicin into SLNs: A Viable Option for Managing its Bioavailability Issues Upon Co-Delivery with Isoniazid.
    Singh H; Sood R; Chaira T; Khanna A; Upadhaya DJ; Bambal R; Bhatnagar PK; Singh M; Kaur IP
    Curr Drug Deliv; 2020; 17(4):343-347. PubMed ID: 32077827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against
    Hakkimane SS; Shenoy VP; Gaonkar SL; Bairy I; Guru BR
    Int J Nanomedicine; 2018; 13():4303-4318. PubMed ID: 30087562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very fast dissolving acid carboxymethylcellulose-rifampicin matrix: Development and solid-state characterization.
    Luciani-Giacobbe LC; Ramírez-Rigo MV; Garro-Linck Y; Monti GA; Manzo RH; Olivera ME
    Eur J Pharm Sci; 2017 Jan; 96():398-410. PubMed ID: 27721041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations.
    Wang Y; Liu H; Liu K; Sun J; He Z
    Pharm Dev Technol; 2013; 18(2):401-6. PubMed ID: 22339279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal.
    Battini S; Mannava MKC; Nangia A
    J Pharm Sci; 2018 Jun; 107(6):1667-1679. PubMed ID: 29462633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of rifampicin in dissolution medium in presence of isoniazid.
    Shishoo CJ; Shah SA; Rathod IS; Savale SS; Kotecha JS; Shah PB
    Int J Pharm; 1999 Nov; 190(1):109-23. PubMed ID: 10528103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.
    Shishoo CJ; Shah SA; Rathod IS; Savale SS; Vora MJ
    Int J Pharm; 2001 Oct; 228(1-2):53-67. PubMed ID: 11576768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mathematical approach for the simultaneous in vitro spectrophotometric analysis of rifampicin and isoniazid from modified-release anti-TB drug delivery systems.
    du Toit L; Pillay V; Choonara Y
    Curr Drug Deliv; 2010 Jan; 7(1):5-12. PubMed ID: 19863485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mesoporous silicon/poly-(DL-lactic-co-glycolic) acid microsphere for long time anti-tuberculosis drug delivery.
    Xu W; Wei X; Wei K; Cao X; Zhong S
    Int J Pharm; 2014 Dec; 476(1-2):116-23. PubMed ID: 25271077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis.
    Nyazema NZ; Rabvukwa P; Gumbo J; Ndudzo P; Chitemerere C
    Cent Afr J Med; 1999 Jun; 45(6):141-4. PubMed ID: 10695183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
    Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
    Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH.
    Singh H; Bhandari R; Kaur IP
    Int J Pharm; 2013 Mar; 446(1-2):106-11. PubMed ID: 23410991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin.
    Avachat AM; Bhise SB
    Pharm Dev Technol; 2011 Apr; 16(2):127-36. PubMed ID: 20105081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D Printed Housing Devices for Segregated Compartmental Delivery of Oral Fixed-Dose Anti-Tubercular Drugs Adopting Print and Fill Strategy.
    Malakar TK; Chaudhari VS; Dwivedy SK; Murty US; Banerjee S
    3D Print Addit Manuf; 2022 Dec; 9(6):535-546. PubMed ID: 36660743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.
    Pienaar E; Linderman JJ; Kirschner DE
    PLoS One; 2018; 13(5):e0196322. PubMed ID: 29746491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capacity of Abbott RealTi
    Hofmann-Thiel S; Molodtsov N; Duffner C; Kadyrov A; Kalmambetova G; Kabirov O; Rajabov A; Parpieva N; Sayfutdinov Z; Vogel M; Vogel H; Antonenka U; Hoffmann H
    Int J Tuberc Lung Dis; 2019 Apr; 23(4):458-464. PubMed ID: 31064625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.